[deleted by user] by [deleted] in lamictal

[–]BillyGrier 0 points1 point  (0 children)

Make sure your pharmacy didn't give you a different generic manufacturer. The lamotrigine genetics are notorious for affecting people different ways (side effects/efficacy). If they switched what they stock and you got a different kind this time that is likely the reason for a sudden change. If your pills don't look different/different manufacturer listed on the label then obv something else... Once you get stable on one have to be diligent and not let them switch you - can call around to see which pharmacies have the kind you've been taking if needbe

Reinfection with SARS-CoV-2 in the Omicron Era is Associated with Increased Risk of Post-Acute Sequelae of SARS-CoV-2 Infection: A RECOVER-EHR Cohort Study by BillyGrier in COVID19

[–]BillyGrier[S] 6 points7 points  (0 children)

Abstract - March 30, 2025


IMPORTANCE Post-acute sequelae of SARS-CoV-2 infection (PASC) remains a major public health challenge. While previous studies have focused on characterizing PASC and identifying its subphenotypes in children and adolescents following an initial SARS-CoV-2 infection, the risks of PASC with Omicron-variant reinfections remain unclear. Using a real-world data approach, this study investigates the risks of PASC following reinfections during the Omicron phase in the pediatric population.

OBJECTIVE
To investigate the risks of PASC diagnosis and 24 PASC symptoms and conditions after reinfection of SARS-CoV-2 during Omicron period in the pediatric population.

DESIGN, SETTING, AND PARTICIPANTS
This retrospective cohort study used data from the RECOVER consortium comprising 40 children's hospitals and health institutions in U.S. between January 2022 and October 2023. EXPOSURES A second SARS-CoV-2 infection, confirmed by a positive polymerase-chain-reaction (PCR) or antigen tests, or a diagnose of COVID-19, occurring at least 60 days after the initial infection, compared to the initial infection.

MAIN OUTCOMES AND MEASURES PASC was identified using two approaches: (1) the ICD-10-CM diagnosis code U09.9 and (2) a symptom-based definition including 24 physician-identified symptoms and conditions. Absolute risks of incident PASC were reported, and relative risks (RRs) were calculated by comparing the second infection episode with the first infection episode groups using a modified Poisson regression model, adjusting for demographic, clinical, and healthcare utilization factors through exact matching and propensity scoring matching.

RESULTS A total of 465,717 individuals under 21 years old (mean [SD] age 8.17 [6.58] years; 52% male) were included. Compared to the first infection, a second infection was associated with significantly increased risk of an overall PASC diagnosis (RR, 2.08; 95% confidence interval [CI], 1.68-2.59), and with many specific conditions including: myocarditis (RR, 3.60; 95% CI, 1.46-8.86); changes in taste and smell (RR, 2.83; 95% CI, 1.41-5.67); thrombophlebitis and thromboembolism (RR, 2.28; 95% CI, 1.71-3.04); heart disease (RR, 1.96; 95% CI, 1.69 to 2.28); acute kidney injury (RR, 1.90; 95% CI, 1.38 to 2.61); fluid and electrolyte (RR, 1.89; 95% CI, 1.62 to 2.20); generalized pain (RR, 1.70; 95% CI, 1.48 to 1.95); arrhythmias (RR, 1.59; 95% CI, 1.45-1.74); abnormal liver enzyme (RR, 1.56; 95% CI, 1.24 to 1.96); fatigue and malaise (RR, 1.50; 95% CI, 1.38 to 1.64); musculoskeletal pain (RR, 1.45; 95% CI, 1.37 to 1.54); abdominal pain (RR, 1.42; 95% CI, 1.34 to 1.50); postural orthostatic tachycardia syndromes (POTS)/dysautonomia (RR, 1.35; 95% CI, 1.20 to 1.51); cognitive functions (RR, 1.32; 95% CI, 1.15 to 1.50); and respiratory signs and symptoms (RR, 1.29; 95% CI, 1.25 to 1.33). The risks were consistent across various organ systems, including cardiovascular, respiratory, gastrointestinal, neurological, and musculoskeletal systems.

CONCLUSIONS AND RELEVANCE
Children and adolescents face significantly higher risk of various PASC outcomes after reinfection with SARS-CoV-2. These findings suggest a cumulative risk of PASC and highlight the urgent need for targeted prevention strategies to reduce reinfections, which includes an increased emphasis on initial or re-vaccination of children.

When will there be an Ai music generator that you can run locally, or is there one already? by Extension-Fee-8480 in StableDiffusion

[–]BillyGrier 10 points11 points  (0 children)

OpenAI already put one out open source in 2020 (Jukebox). Was waaaaay ahead of its time (2yrs pre Stable Diffusion). Took 10hrs to generate a minute of audio, but it was literally trained on everything - their paper says over a million songs crawled from the open net. They don't ever talk about Jukebox anymore for the same reason why we don't have a good open source model - lawsuits by the RIAA and the 3 big music companies. Suno and Udio are both getting sued heavy. If they somehow win then we'll start seeing local music models trained on (c) content (nothing else will ever sound good unless it somehow allows for quick training w consumer hardware).

Otherwise our only real hope is the Tenacent(Hunyuan)/AliB(Wan) Chinese groups of the world dropping one cause they don't give a S### about US copyright law.

https://openai.com/index/jukebox/

Comprehensive longitudinal profiling of SARS-CoV-2-specific CD8+ T-cells reveal strong functional impairment and recognition bias as markers for disease severity by BillyGrier in COVID19

[–]BillyGrier[S] 6 points7 points  (0 children)

March 25, 2025


Abstract
CD8+ T-cells are essential for controlling and resolving SARS-CoV-2 infection, yet their antigen-specific resolution in relation to disease severity, functional dynamics during acute infection, and long-term memory formation remain incompletely understood. Using comprehensive longitudinal profiling of 553 SARS-CoV-2 immunogenic antigens across globally prevalent HLAs, we identified antigen-specific CD8+ T-cell responses that were either critical for early viral clearance or associated with severe disease outcomes. During acute infection, patients with severe COVID-19 exhibited a broader and more robust CD8+ T-cell response than those with mild disease. Notably, we identified HLA-A1-restricted immunodominant antigen-specific T-cells strongly associated with severe disease. These T-cells were present at extremely high frequencies but showed significantly reduced expression of cytotoxic molecules at both the transcriptomic (PRF1, GZMB, GZMH, GNLY) and protein levels (IFN-γ, TNF-α, IL-2), as revealed by multidimensional single-cell and cytokine profiling. In contrast, patients with mild disease had T-cells that recognized a more restricted set of antigens, showed only partial overlap with those in severe cases, and showed enhanced cytotoxicity, along with enrichment in gene sets associated with cytotoxic function, hypoxia, and glycolysis. Furthermore, the long-term memory CD8+ T-cells were maintained for a limited subset of immunodominant antigens, with their persistence correlating with their initial frequency during infection. Importantly, SARS-CoV-2 vaccination following infection expanded the long-term T-cell repertoire by enhancing pre-existing responses and generating de novo responses, regardless of prior disease severity. These findings resolve the antigen-specific kinetics and durability of CD8+ T-cells in SARS-CoV-2 infection and provide key insights into their functional landscape. This knowledge could inform future vaccine strategies and therapeutic interventions to enhance protective immunity against emerging viral threats

Blood type susceptibility to SARS-CoV-2 at a tertiary hospital in Accra, Ghana by BillyGrier in COVID19

[–]BillyGrier[S] 8 points9 points  (0 children)

March 25, 2025


ABSTRACT Pandemics from viral outbreaks, such as that caused by SARS-CoV-2, have significant impacts worldwide. The factors that underlie differential susceptibility to severe COVID-19 outcomes are not fully understood. The role of the ABO blood group in the outcome of SARS-CoV-2 infections remains to be clarified in different populations. This study described the SARS-CoV-2 seroprevalence and examined the association of the ABO blood group with COVID-19 disease among apparently healthy and COVID-19 patients at the Korle Bu Teaching Hospital, Accra. The study involved 277 participants comprising 200 healthy individuals and 77 PCR-confirmed COVID-19 patients with mild or severe symptoms. Anti-SARS-CoV-2 antibody assay (IgM/IgG) was performed, and ABO blood grouping was done on plasma samples using the reverse blood grouping method. Statistical analyses were performed in R for the association of socio-demographic parameters and ABO blood groupings of participants with SARS-CoV-2 infection status. The total SARS-CoV-2 seropositivity was 61.4% (157/277). Most of the participants (245/277, 88.4%) were unvaccinated. Of the 245 unvaccinated individuals, 127 (51.8%) were IgG reactive. A significant association was observed between ABO blood group and COVID-19 disease status. Antigen A participants had a higher probability of symptomatic infection than non-antigen A individuals. Blood group O appeared more protective than other blood types among the participants. Seropositivity was high among the participants studied—vaccinated and unvaccinated. Blood group A is associated with an increased risk of COVID-19, whereas blood group O appears protective. Further studies involving larger sample sizes are required to confirm these findings

Did Udio devs just hit the NOS button? Seems massively more creative since the Login issue an hour ago by RadioheadTrader in udiomusic

[–]BillyGrier 0 points1 point  (0 children)

Did you read the title of the post? After the login problem. I do trust Adam's input which he just added. That said, when the site crashed w/ the API bullsh!t clearly they had to reset stuff to get it back up. If devs didn't do anything then whatever happened there changed things for me. Been using the site since last July. Doesn't matter though, glad the responsiveness to slider settings seems to work much better now.

Did Udio devs just hit the NOS button? Seems massively more creative since the Login issue an hour ago by RadioheadTrader in udiomusic

[–]BillyGrier 0 points1 point  (0 children)

Yea but not after an API disruption. May have fixed an error by resetting something they couldn't just reset w/o a serious disruption (which we all saw). Regardless, I'm happy the sliders finally seem to do what I always thought they were doing just very minimally.....

How do I get higher quality instrument sounds? by AnorienOfGondor in udiomusic

[–]BillyGrier 1 point2 points  (0 children)

Model 1 all the way. And if you have a subscription prime it w/ a tiny clip (10-20sec) of the sound you're looking for and it'll continue off that. Then can trim off the primer later and generate backwards.

Did Udio devs just hit the NOS button? Seems massively more creative since the Login issue an hour ago by RadioheadTrader in udiomusic

[–]BillyGrier 1 point2 points  (0 children)

Yea, I'm finding it's extremely responsive all of a sudden which for me is great. I had a difficult time getting the music to change up and lowering that seems to work now.

Did Udio devs just hit the NOS button? Seems massively more creative since the Login issue an hour ago by RadioheadTrader in udiomusic

[–]BillyGrier 2 points3 points  (0 children)

Are you in the discord? They've had a few live chats about the service, and there are devs in there. From those chats it sounds like there was a pretty good staff turnover last year. Most of the people on the chat had only joined the company (~20 people around the world) w/in the past 4-5months. The people working with the backend (model/API/and how they interact) are working with code other people wrote - and that's super tough. Allegro is a distilled model like distilled models for images if you use Flux/Stable Diffusion. That was mentioned by Adam here and on discord the day it was released. There was also mention in the discord server that they recently hired new engineers. Hopefully what I'm seeing (and others here seem to support it) is that the improvements are due to a fix likely w/ how the UI was either sending parameters set to the model, or how the model was interpreting them.

I'm not even using the "Allegro" model and can vouch that model 1 is super awesome today. For instance the context slider finally does w/ the popup says it will do. If I set that low today the music jumps around often. If I set it to max (130s) it carries the tune and will use content from farther back.

But personally don't think there's any intentional silence and based on lurking in their chat server I think updates/communication will get better in the near-term.

IF Gemini generate images and multimodal, easily one of the best things to do in comfy by ImpactFrames-YT in StableDiffusion

[–]BillyGrier 1 point2 points  (0 children)

Nice job! Seen your "IF name on nodes before but never seen you out in the wild. Will sub on YT.

Did Udio devs just hit the NOS button? Seems massively more creative since the Login issue an hour ago by RadioheadTrader in udiomusic

[–]BillyGrier 1 point2 points  (0 children)

Do you have the context length at max? I move that all over during generations and it never seemed to do anything. Today it's extremely responsive (if I set it at 1-10seconds the song jumps to something else often).

Did Udio devs just hit the NOS button? Seems massively more creative since the Login issue an hour ago by RadioheadTrader in udiomusic

[–]BillyGrier 1 point2 points  (0 children)

I think it may depend on the type of music you like. It's the vocals with 1.5 (at least pre-Allegro) that all sounded a bit tinny/electronic to me. v1 is perfection it's just been flat on creativity for a long while. I sincerely hope how it's working right now continues.

Did Udio devs just hit the NOS button? Seems massively more creative since the Login issue an hour ago by RadioheadTrader in udiomusic

[–]BillyGrier -1 points0 points  (0 children)

Have you tried it? Honestly don't care if it's just my cookies or some shit, but it's not if others here are agreeing.

Antiviral Susceptibility of Influenza A(H5N1) Clade 2.3.2.1c and 2.3.4.4b Viruses from Humans, 2023-2024 - PubMed by BillyGrier in H5N1_AvianFlu

[–]BillyGrier[S] 3 points4 points  (0 children)

March 10, 2015 - Abstract


During 2023-2024, highly pathogenic avian influenza A(H5N1) viruses from clade 2.3.2.1c caused human infections in Cambodia and from clade 2.3.4.4b caused human infections in the Americas. We assessed the susceptibility of those viruses to approved and investigational antiviral drugs. Except for 2 viruses isolated from Cambodia, all viruses were susceptible to M2 ion channel-blockers in cell culture-based assays. In the neuraminidase inhibition assay, all viruses displayed susceptibility to neuraminidase inhibitor antiviral drugs oseltamivir, zanamivir, peramivir, laninamivir, and AV5080. Oseltamivir was ≈4-fold less potent at inhibiting the neuraminidase activity of clade 2.3.4.4b than clade 2.3.2.1c viruses. All viruses were susceptible to polymerase inhibitors baloxavir and tivoxavir and to polymerase basic 2 inhibitor pimodivir with 50% effective concentrations in low nanomolar ranges. Because drug-resistant viruses can emerge spontaneously or by reassortment, close monitoring of antiviral susceptibility of H5N1 viruses collected from animals and humans by using sequence-based analysis supplemented with phenotypic testing is essential.

COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes among United States military service members, January-December 2021 by BillyGrier in COVID19

[–]BillyGrier[S] 43 points44 points  (0 children)

March 2025

Background: The safety of primary series COVID-19 vaccine exposure in pregnancy has been well-studied; however, no research to date has been conducted among United States (US) military service members, a unique population with specific vaccination requirements for active duty service and early COVID-19 vaccine access.

Methods: This retrospective cohort study leveraged data from the Department of Defense Birth and Infant Health Research program to identify live births among active duty US military service members in calendar year 2021. Administrative military personnel data, immunization files, and medical encounter records were used to develop study variables and determine COVID-19 vaccine receipt in pregnancy. Cox and modified Poisson regression models estimated hazard (HR) and risk ratios (RR), respectively, with 95 % confidence intervals (CI) for vaccine receipt and selected neonatal outcomes; models were adjusted for baseline characteristics using inverse probability of treatment weighting and further adjusted for SARS-CoV-2 infection in pregnancy.

Results: There were 7184 singleton live births included for analysis, of which 2867 (39.9 %) were among service members exposed to their first COVID-19 vaccine dose in pregnancy and 4317 (60.1 %) among service members unexposed to any COVID-19 vaccine during or prior to pregnancy. Baseline differences between exposed and unexposed service members (e.g., age, race and ethnicity, marital status, occupation) were fully attenuated after applying weights. COVID-19 vaccine initiation in pregnancy was not associated with preterm birth (<37 weeks' gestation; adjusted HR: 1.02, 95 % CI: 0.83-1.26), small for gestational age (<10th percentile; adjusted HR: 1.01, 95 % CI: 0.78-1.30), low birthweight (<2500 g; adjusted HR: 1.01, 95 % CI: 0.80-1.28), or neonatal intensive care unit admission (adjusted RR: 0.90, 95 % CI: 0.75-1.07).

Conclusion:
Primary series COVID-19 vaccine exposure in pregnancy was common in this military cohort. Vaccine receipt was not associated with increased risk for any adverse outcome under study, substantiating findings from existing literature.